Evidence map›Paper›PMID 41344335›Full record

ArticleRenal failure2025

Comparative effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on prognosis in non-dialysis chronic kidney disease: a propensity-matched cohort study.

Yi-Chou Hou, Chia-Lin Wu, Wei-Cheng Tseng, Joshua Wang, Kuo-Cheng Lu, Cai-Mei Zheng, Jia-Sin Liu, Ko-Lin Kuo, Der-Cherng Tarng

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yi-Chou HouDepartment of Internal Medicine, Division of Nephrology, Cardinal Tien Hospital, New Taipei City, Taiwan.ORCID 0000-0001-7662-9890
Chia-Lin WuDepartment of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.ORCID 0000-0001-6045-6956
Wei-Cheng TsengDivision of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Joshua WangDepartment of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
Kuo-Cheng LuSchool of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Cai-Mei ZhengDivision of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.ORCID 0000-0003-0370-3951
Jia-Sin LiuDivision of Nephrology, Department of Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
Ko-Lin KuoDivision of Nephrology, Department of Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.ORCID 0000-0002-7477-0388
Der-Cherng TarngDivision of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID 0000-0001-9017-2081

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal anemia in patients with stage-IV chronic kidney disease (CKD) is commonly treated with erythropoiesis-stimulating agents (ESAs), which are effective but associated with cardiovascular risks, variable responsiveness, and inflammatory complications. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have recently emerged as an alternative therapy that enhances endogenous erythropoietin production and improves iron metabolism. This retrospective cohort study utilized the TriNetX Global Collaborative Network to compare clinical outcomes between HIF-PHI and ESA users in non-dialysis stage IV CKD patients (estimated glomerular filtration rate 15-30 mL/min/1.73 m

Indexed as

AnemiaHematinicsHypoxia-Inducible Factor-Proline DioxygenasesProlyl-Hydroxylase InhibitorsRenal Insufficiency, ChronicAgedFemaleGlomerular Filtration RateHumansMaleMiddle AgedPrognosisPropensity ScoreRetrospective StudiesTreatment OutcomeHematinicsHypoxia-Inducible Factor-Proline DioxygenasesProlyl-Hydroxylase InhibitorsChronic kidney diseaseerythropoiesis-stimulating agentshypoxia-inducible factor prolyl hydroxylase inhibitorsrenal anemiasepsis

Identifiers

PMID41344335
PMCPMC12679846

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.